Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation

被引：57

作者：

Jurisic, Vladimir ^{[1
]}

Obradovic, Jasmina ^{[2
]}

Pavlovic, Sonja ^{[3
]}

Djordjevic, Natasa ^{[1
]}

机构：

[1] Univ Kragujevac, Fac Med Sci, Svetozara Markovica 69, Kragujevac 34000, Serbia

[2] Univ Kragujevac, Fac Sci, Inst Biol & Ecol, Radoja Domanovica 12, Kragujevac 34000, Serbia

[3] Univ Belgrade, Inst Mol Genet & Genet Engn, Vojvode Stepe 444a, Belgrade 11010, Serbia

来源：

ANALYTICAL CELLULAR PATHOLOGY | 2018年 / 2018卷

关键词：

GENOME-WIDE ASSOCIATION; EGFR GENE; TYROSINE KINASE; COPY NUMBER; TRANSCRIPTION FACTOR; ACQUIRED-RESISTANCE; PLEURAL METASTASIS; SIGNALING PATHWAYS; TARGETED THERAPY; PROTEIN-BINDING;

D O I：

10.1155/2018/6192187

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recently, epidermal growth factor receptor (EGFR) was a key molecule in investigation of lung cancer, and it was a target for a new therapeutic strategy, based on molecular analyses. In this review, we have summarized some issues considering the role of EGFR in lung cancer, its coding gene, and its promoter gene polymorphisms (SNPs) -216G/T and -191C/A in non-small-cell lung cancer (NSCLC). The position of the SNPs indicates their significant role in EGFR regulation. The accumulation of knowledge regarding SNPs lately suggests their significant and important role in the onset of carcinogenesis, the prediction of the onset of metastases, the response to therapy with TKI inhibitors, and the onset of toxic effects of the applied therapy. Based on this, we suggest further studies of the relationship of clinical significance to SNPs in patients with lung tumors.

引用

页数：9

共 113 条

[51] Investigation of NK cell function and their modulation in different malignancies [J].

Konjevic, Gordana ;

Jurisic, Vladimir ;

Jovic, Viktor ;

Vuletic, Ana ;

Martinovic, Katarina Mirjacic ;

Radenkovic, Sandra ;

Spuzic, Ivan .

IMMUNOLOGIC RESEARCH, 2012, 52 (1-2) :139-156

[52] Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial [J].

Kris, MG ;

Natale, RB ;

Herbst, RS ;

Lynch, TJ ;

Prager, D ;

Belani, CP ;

Schiller, JH ;

Kelly, K ;

Spiridonidis, H ;

Sandler, A ;

Albain, KS ;

Cella, D ;

Wolf, MK ;

Averbuch, SD ;

Ochs, JJ ;

Kay, AC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16) :2149-2158

[53] EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib [J].

Larsen, Anne Winther ;

Nissen, Peter Henrik ;

Meldgaard, Peter ;

Weber, Britta ;

Sorensen, Boe Sandahl .

LUNG CANCER, 2014, 85 (03) :435-441

[54] Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib [J].

Liu, G. ;

Gurubhagavatula, S. ;

Zhou, W. ;

Wang, Z. ;

Yeap, B. Y. ;

Asomaning, K. ;

Su, L. ;

Heist, R. ;

Lynch, T. J. ;

Christiani, D. C. .

PHARMACOGENOMICS JOURNAL, 2008, 8 (02) :129-138

[55]

Liu TC, 2017, AM J CANCER RES, V7, P187

[56] Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NC160 cell lines [J].

Liu, Wanqing ;

Wu, Xiaolin ;

Zhang, Wei ;

Montenegro, Raquel C. ;

Fackenthal, Donna Lee ;

Spitz, Jared A. ;

Huff, Lyn Mickley ;

Innocenti, Federico ;

Das, Soma ;

Cook, Edwin H., Jr. ;

Cox, Nancy J. ;

Bates, Susan E. ;

Ratain, Mark J. .

CLINICAL CANCER RESEARCH, 2007, 13 (22) :6788-6795

[57] Functional EGFR Germline Polymorphisms May Confer Risk for EGFR Somatic Mutations in Non-Small Cell Lung Cancer, with a Predominant Effect on Exon 19 Microdeletions [J].

Liu, Wanqing ;

He, Lijun ;

Ramirez, Jacqueline ;

Krishnaswamy, Soundararajan ;

Kanteti, Rajani ;

Wang, Yi-Ching ;

Salgia, Ravi ;

Ratain, Mark J. .

CANCER RESEARCH, 2011, 71 (07) :2423-2427

[58]

Liu WQ, 2005, CANCER RES, V65, P46

[59] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[60] Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib [J].

Ma, Fei ;

Sun, Tong ;

Shi, Yuankai ;

Yu, Dianke ;

Tan, Wen ;

Yang, Ming ;

Wu, Chen ;

Chu, Datong ;

Sun, Yan ;

Xu, Binghe ;

Lin, Dongxin .

LUNG CANCER, 2009, 66 (01) :114-119

← 1 2 3 4 5 6 7 8 9 10 →